Abstract
Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment which induces selective immunogenic cell death in targeted cells [1-3]. NIR-PIT utilizes an antibody–photoabsorber conjugate (APC) which is activated after tumour binding by NIR light (typically administered as laser light). A large body of research has developed around NIR-PIT, showing that it can kill many types of cancer cell by targeting unique transmembrane proteins overexpressed on the cell surface. Currently on the clinical side, a global phase III clinical trial of NIR-PIT for inoperable head and neck cancer patients is currently underway using an anti-epidermal growth factor receptor (EGFR)-antibody IR700 conjugate (https://clinicaltrials.gov/ct2/show/NCT03769506).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
